Tests safety of plamotamab in adults with rheumatoid arthritis
Tests plamotamab's safety in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
Key facts
- Where
- Chisinau, MoldovaSee the site
- Phase
- Phase 1
Where in Moldova
- ChisinauChisinau, MoldovaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xencor, Inc.
- Trial code
- NCT07230353
- Record updated
- 3 August 2026
- Original description
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.Read full original descriptionShow less
A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
Inclusion: Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening; Inadequate response to, loss of response to, or intolerance to available RA therapies; Stable doses of RA medications prior to screening; Use of highly effective methods of contraception.
Exclusion: Major surgery within 12 weeks prior to screening or planned within 12 months after dosing; Recurrent infections or active clinically significant infection; Active or untreated latent tuberculosis; Cancer or history of cancer or lymphoproliferative disease within the previous 5 years; Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease; Note: Additional, more specific inclusion/exclusion criteria are defined in the protocol.